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provide durable PFS and OS in this high risk cohort. Trans-
formation to DLBCL > 1 year after dx of FL is associated with
improved 1 yr PFS in both autoHCT and alloHCT groups, and
superior 2 yr OS in the alloHCT group compared to those
cases with transformation< 1year from dx of FL. Patients
with primary induction failure also beneﬁt from consolida-
tion with HCT.PEDIATRIC DISORDERS ORAL87
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Treosulfan has several characteristics that make it
appealing for use in conditioning, including bypass of
hepatic enzyme activation, a highly predictable pharma-
cokinetic proﬁle, and sufﬁcient immunosuppressive
activity to allow for engraftment of donor cells across
histocompatibility barriers. Here we report the preliminary
results of a phase II multi-center clinical trial for 25
patients with non-malignant diseases [primary immune
deﬁciency diseases (PIDD, n¼12), hemophagocytic lym-
phohistiocytosis (HLH; n¼5), inherited bone marrow
failure syndromes (n¼4), and other non-malignant
diseases (n¼4)] who received allogeneic hematopoietic cell
transplantation (HCT) from October 2009 to July 2012.
Patients were given HLA-matched related (n¼2) or unre-
lated (n¼23) marrow (n¼23) or G-CSF mobilized periph-
eral blood stem cell (n¼2) grafts following conditioning
with treosulfan (total dose: 42 grams/m2), ﬂudarabine
(total dose: 150 mg/m2), +/- thymoglobulin (rabbit ATG,
n¼16; total dose: 6 mg/kg). All patients received tacroli-
mus and methotrexate for GVHD prevention. Median age
at HCT was 8.3 (range, 0.4-30.5) years. Three patients had
received a previous allogeneic HCT. Median time to
neutrophil engraftment was 22 days. Of the 25 evaluable
patients, all had full (>95%; n¼19) or mixed (50-94%, n¼3;
6-49%, n¼3) donor CD3+ T-cell chimerism. One patient
with sickle cell disease who received a very low total
nucleated cell dose required a stem cell boost due to poor
graft function. With a median follow-up for survivors of 12
(range, 2-35) months, the 1-year survival was 86%. Three
patients died; one died from GVHD 5 months after HCT,
one died at 4 months from an unrelated surgical compli-
cation, and one died at 8 months from recurrent CNS HLH.
None of the patients developed sinusoidal obstructive
syndrome. One patient was intubated for airway protec-
tion in the setting of herpes stomatitis. The cumulative
incidence of grades III-IV acute GVHD at 100 days and 1-
year chronic GVHD were 12% and 25%, respectively.
Patients who received ATG had a signiﬁcantly lower inci-
dence of grade III-IV acute GVHD (0% compared to 33%;P ¼ .02). Our results to date indicate that the combination
of treosulfan, ﬂudarabine, and rabbit ATG is effective at
establishing donor engraftment with a low toxicity proﬁle.
These results suggest that the reduction of regimen-
related toxicities will translate into improved survival
outcomes in patients with PIDD and other non-malignant
diseases, and support the need for future disease-speciﬁc
clinical trials.
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From August 2000 to November 2011, 127 children
under the age of 18 years with acquired severe aplastic
anemia (SAA) received hematopoietic stem cell trans-
plantation (HSCT) in one of the 10 Asia Paciﬁc institutions
of the VABMT Consortium, including 53 with matched
sibling donor (MSD) and 74 with alternative donor (AD).
Among these 74 AD, 22 were matched unrelated donor
(MUD), 32 were mismatched unrelated donor (MMUD) and
20 were mismatched related donor (MMRD). Although the
MSD group developed less grade II-IV acute GVHD
compared to the AD group (14.3% vs 32.8%, P ¼ .029), there
was no signiﬁcant difference in grade III-IV GVHD (10.2%
vs 12.5%, P ¼ .774) or chronic GVHD (19.6% vs 35.0%, P ¼
.088). After a median follow-up of 33.5 months, the inci-
dence of graft failure and 3-year overall survival were
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P ¼ .658; 90.2% vs 82.1%, P ¼ .201; respectively). With an
excellent outcome in MUD HSCT (95.5% 3-year survival),
the survival rate of the matched donor group (MSD+MUD)
collectively was much better than that of the mismatched
group (MMRD+MMUD) (91.6% vs 76.1%, P ¼ .019). In
univariate analysis, conditioning without radiation was the
only risk factor for graft failure (P¼.045). Grades II-IV acute
GVHD (P ¼ .013) and graft failure (p¼0.001) were risk
factors for poor survival. In multivariate analysis, only graft
failure was signiﬁcantly associated with survival proba-
bility (P ¼ .012). Collectively, these data suggest that
conditioning with radiation is important for engraftment
and successful HSCT. MUD HSCTs are highly successful and
may be considered a ﬁrst line therapy in the absence of
MSD.89
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Introduction: Bone marrow transplantation (BMT) is cura-
tive for hemoglobinopathies but its utilization in sickle cell
disease (SCD) is sparse. Though there were 100,000 affected
with SCD in the USA, BMT has been utilized in less than 1000
individuals. As SCD has variable clinical course, confusion
prevails regarding indication, timing of BMT, beneﬁts and
risks for individuals due to morbidity/mortality of the
procedure.
Methods: We used the Pediatric Health Information System
(PHIS), an electronic database of children's hospitals in the
US. Patients under the age of 21 who underwent BMT at one
of the 26 PHIS hospitals from 2000-2011 were analyzed. We
abstracted data on demographics, hospitalizations, BMT and
related complications.
Results: From 2000 to 2011, there were 1365 unique
pediatric patients with SCD were identiﬁed. Among these
228 (17%) children underwent BMT and their demographic
and baseline characteristics are shown in Figure 1A.
Overall, the number of new patients with SCD getting
hospitalized has decreased consistently whereas children
undergoing BMT has increased (Figure 1B). There was
a signiﬁcant decrease in hospitalizations after BMT
compared to pre-BMT state (median hospitalization 2 vs. 4
respectively, n¼173, P  .0001). After BMT, 6% (13/228) of
patients developed stroke, 14% (31/228) had CMV infec-
tion, 9% (21/228) developed invasive fungal infections,
2.2% (5/228) had VOD, and 23% (24/102) developed GVHD.
Seventeen patients (7.4%) died related to BMT with more
deaths occurred when BMT performed at age 11 years
compared to age 210 years (13/108 vs. 4/120 respectively,
P ¼ .029).
Conclusions: We show an increasing trend of BMT utiliza-
tion in children with SCD. In this largest BMT cohort of SCD,
transplant related mortality is very low especially if BMT is
performed before 10 years of age. BMT signiﬁcantly
decreases the overall hospitalizations in these patients.
Studies addressing the barriers of BMT and hydroxyurea
utilization are needed to decrease the health burden in this
chronic disease.Figure 1A. Baseline characteristics of SCD patients underwent BMT.
Figure 1B. Overall trend of new SCD diagnosis and BMT in children and
adoloscents.
